1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7-30.

2. Kay FU, Kandathil A, Batra K, Saboo SS, Abbara S, et al. Revisions to the Tumor, Node, Metastasis staging of lung cancer (8(th) edition): Rationale, radiologic findings and clinical implications. World J Radiol 2017;9:269-79.

3. American Cancer Society. Be Inspired by the Words and Music of Hope. Available from: [Last accessed on 20 Jul 2020].

4. Wang H, Udukala DN, Samarakoon TN, Basel MT, Kalita M, et al. Nanoplatforms for highly sensitive fluorescence detection of cancer-related proteases. Photochem Photobiol Sci 2014;13:231-40.

5. Udukala DN, Wang H, Wendel SO, Malalasekera AP, Samarakoon TN, et al. Early breast cancer screening using iron/iron oxide-based nanoplatforms with sub-femtomolar limits of detection. Beilstein J Nanotechnol 2016;7:364-73.

6. Voelz BE, Kalubowilage M, Bossmann SH, Troyer DL, Chebel RC, et al. Associations between activity of arginase or matrix metalloproteinase-8 (MMP-8) and metritis in periparturient dairy cattle. Theriogenology 2017;97:83-8.

7. Kalubowilage M, Covarrubias-Zambrano O, Malalasekera AP, Wendel SO, Wang H, et al. Early detection of pancreatic cancers in liquid biopsies by ultrasensitive fluorescence nanobiosensors. Nanomedicine 2018;14:1823-32.

8. Callsearch. Homepage. Available from: [Last accessed on 20 Jul 2020].

9. The cobas® EGFR Mutation Test v.2. Available from: [Last accessed on 20 Jul 2020].

10. Bossmann SH. Liquid Biopsies for Early Cancer Detection. In: Park K, editor. Biomaterials for Cancer Therapeutics, 2nd Edition, Evolution and innovation. Amsterdam: Elsevier; 2020. pp. 233-59.

11. Available from: [Last accessed on 24 Jul 2020].

12. Available from: [Last accessed on 24 Jul 2020].

13. Available from: [Last accessed on 24 Jul 2020].

14. Available from: [Last accessed on 24 Jul 2020].

15. Available from: [Last accessed on 24 Jul 2020].

16. Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 2018;359:926-30.

17. Lennon AM, Buchanan AH, Kinde I, Warren A, Honushefsky A. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science 2020;369:eabb9601.

18. Locke WJ, Guanzon D, Ma C, Liew YJ, Duesing KR, et al. DNA methylation cancer biomarkers: translation to the clinic. Front Genet 2019;10:1150.

19. Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol 2020;31:745-59.

20. auf dem Keller U, Doucet A, Overall CM. Protease research in the era of systems biology. Biol Chem 2007;388:1159-62.

21. Langer F, Bokemeyer C. Crosstalk between cancer and haemostasis. Implications for cancer biology and cancer-associated thrombosis with focus on tissue factor. Hamostaseologie 2012;32:95-104.

22. Mason SD, Joyce JA. Proteolytic networks in cancer. Trends Cell Biol 2011;21:228-37.

23. Merchant N, Nagaraju GP, Rajitha B, Lammata S, Jella KK, et al. Matrix metalloproteinases: their functional role in lung cancer. Carcinogenesis 2017;38:766-80.

24. Kayser K, Richter N, Hufnagl P, Kayser G, Kos J, et al. Expression, proliferation activity and clinical significance of cathepsin B and cathepsin L in operated lung cancer. Anticancer Res 2003;23:2767-72.

25. Werle B, Kotzsch M, Lah TT, Kos J, Gabrijelcic-Geiger D, et al. Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer. Anticancer Res 2004;24:4147-61.

26. Terasawa Y, Hotani T, Katayama Y, Tachibana M, Mizuguchi H, et al. Activity levels of cathepsins B and L in tumor cells are a biomarker for efficacy of reovirus-mediated tumor cell killing. Cancer Gene Ther 2015;22:188-97.

27. Kansas State Research Foundation. Protease Assay. USA patent. 2015. 2017 Jun 20; 2017 Aug 15

28. Kansas State Research Foundation. Kansas State Research Foundation. Protease Assay. Canada patent. 2017.

29. Kansas State Research Foundation. Protease Assay. United Kingdom patent. 2014.

30. Das P, Sedighi A, Krull UJ. Cancer biomarker determination by resonance energy transfer using functional fluorescent nanoprobes. Anal Chim Acta 2018;1041:1-24.

31. Craik CS, Page MJ, Madison EL. Proteases as therapeutics. Biochem J 2011;435:1-16.

32. MEROPS release 12.2. Available from: [Last accessed on 20 Jul 2020].

33. Welch BL. The generalization of student’s problem when several different population variances are involved. Biometrika 1947;34:28-35.

34. Coffey CS, Cofield SS. Parametric linear models. Biostatistics 2006;15:223-43.

35. Page RB, Stromberg AJ. Linear methods for analysis and quality control of relative expression ratios from quantitative real-time polymerase chain reaction experiments. Sci. World J 2011;11:1383-93.

36. P value. Available from: [Last accessed on 20 Jul 2020].

37. Bossmann SH, Schulman LS. Luminescence quenching as a probe of particle distribution. 1997.

38. Ben-Avraham D, Schulman LS, Bossmann SH, Turro C, Turro NJ. Luminescence quenching of Ruthenium(II)-Tris(phenanthroline) by Cobalt(III)-Tris(phenanthroline) bound to the surface of starburst dendrimers. J Phys Chem B 1998;102:5088-93.

39.  Aruna, Li LM. Overexpression of golgi membrane protein 1 promotes non-small-cell carcinoma aggressiveness by regulating the matrix metallopeptidase 13. Am J Cancer Res 2018;8:551-67.

40. Boon L, Ugarte-Berzal E, Vandooren J, Opdenakker G. Glycosylation of matrix metalloproteases and tissue inhibitors: present state, challenges and opportunities. Biochem J 2016;473:1471-82.

Journal of Cancer Metastasis and Treatment
ISSN 2454-2857 (Online) 2394-4722 (Print)


All published articles are preserved here permanently:


All published articles are preserved here permanently: